What Documentation Gets a GLP-1 Prior Authorization Approved?

The packet, item by item

1. The diagnosis, written so it matches an approved indication

The reviewer checks the diagnosis against what the drug is approved to treat, and indications are not interchangeable across GLP-1s.

Wegovy injection is indicated, in combination with a reduced calorie diet and increased physical activity, to reduce excess body weight in adults with obesity, or in adults with overweight in the presence of at least one weight-related comorbid condition. Wegovy tablets are indicated, in combination with a reduced calorie diet and increased physical activity, to reduce excess body weight in adults with obesity or with overweight in the presence of at least one weight-related comorbid condition.

Zepbound (tirzepatide) is FDA-indicated, in combination with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults with overweight in the presence of at least one weight-related comorbid condition. Zepbound is also FDA-indicated, in combination with a reduced-calorie diet and increased physical activity, to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity.

The diabetes drugs are different. Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. The Mounjaro FDA-approved indication is limited to glycemic control in type 2 diabetes mellitus; chronic weight management is not an approved indication under the Mounjaro label. Likewise, OZEMPIC injection is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, and all three OZEMPIC injection indications are restricted to adults with type 2 diabetes mellitus.

For context, the obesity eligibility threshold used in the Zepbound weight-reduction registration trials was a BMI of 30 kg/m2 or greater, and the overweight eligibility threshold used in the Zepbound weight-reduction registration trials was a BMI of 27 to less than 30 kg/m2 together with at least one weight-related comorbid condition. Those are trial thresholds, not a given plan's rule; plans write their own criteria (see below).

2. The exact product, strength, and form

Wegovy is marketed in two distinct dosage forms under a single brand name and a single FDA label: WEGOVY (semaglutide) injection, solution, and WEGOVY (semaglutide) tablet. Prescribers must specify which form is intended, as dosing schedules and indications differ between them.

Two other products have no oral form at all. Zepbound is administered exclusively as a subcutaneous injection; the FDA label describes it only as 'injection, for subcutaneous use' and no oral dosage form of Zepbound is listed in the label. Mounjaro is an injection for subcutaneous use only; it is not an oral tablet or capsule.

And strengths do not map across brands. OZEMPIC tablet strengths (1.5 mg, 4 mg, 9 mg) are different from the RYBELSUS tablet strengths (3 mg, 7 mg, 14 mg) on the same shared label, so the two brands are not interchangeable milligram-for-milligram.

3. The record of what came before it

If the drug is not on the plan's list, there is a defined path. A formulary is the list of prescription drugs covered by a prescription drug plan or other insurance plan offering prescription drug benefits. An enrollee has the right to follow their insurance company's drug exceptions process, which allows them to get a prescribed drug that is not normally covered by their health plan.

To get a drug covered through the exceptions process the enrollee's doctor must confirm to the health plan, orally or in writing, that the drug is appropriate for the enrollee's medical condition. Federal guidance names three grounds that support such a request:

• All other drugs covered by the plan have not been or will not be as effective as the drug being requested.
• Any alternative drug covered by the plan has caused or is likely to cause side effects that may be harmful to the enrollee.
• Where the plan limits the number of doses allowed, the allowed dosage has not worked for the enrollee's condition.

Each ground is a question the prescriber's note should answer with names, dates, and outcomes rather than a general statement — the skeleton of a documented prior-treatment record.

While you wait: while an enrollee is in the drug exceptions process, the plan may give them access to the requested drug until a decision is made. And if a drug exception is granted, the health plan generally treats the drug as covered and charges the copayment that applies to the most expensive drugs already covered on the plan. Any amount an enrollee pays for a drug obtained through the exceptions process generally counts toward their deductible and maximum out-of-pocket limits.

4. The safety screen

Prescribers are answering label-level safety questions when they sign. Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Zepbound is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Overlapping therapy also matters. Concomitant use of Wegovy tablets or Wegovy injection with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended. Coadministration of Zepbound with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended.

5. The plan's own criteria, in writing

This item is free. A notice of adverse benefit determination must describe the internal guidelines or criterion used in making the determination and inform the consumer that a copy of the internal requirements will be provided free of charge upon request. A notice of adverse benefit determination must also describe any additional information needed to improve or complete the claim, and must state the specific reasons for the determination, including the denial code and its corresponding meaning. Claimants may obtain coding and other information relevant to their claim for benefits free of charge upon request under 29 CFR 2560.503-1(h)(2)(iii).

Request them; they tell you which field the reviewer found missing.

What changes by coverage type — verified as of August 5, 2026

Commercial plans. For patients with commercial insurance, Measured performs a benefits check to determine which medications may be covered under the patient's plan. Measured states that if prior authorization is approved, the patient pays only their plan's copay when picking up the medication from the pharmacy. Measured states that while many patients have GLP-1 copays around $20, actual out-of-pocket cost depends on the patient's specific insurance plan and pharmacy benefits (as published August 5, 2026).

Medicare Part D. Since the inception of the Medicare Part D program, CMS has interpreted the statutory exclusion of 'agents when used for weight loss' to mean anti-obesity medications are coverable under Part D only when used for a medically accepted indication other than weight loss or weight management.

The Medicare GLP-1 Bridge is a short-term demonstration running from July 1, 2026 through December 31, 2027. During that window, eligible Medicare Part D beneficiaries can obtain certain GLP-1 medications, including Zepbound, for a $50 per month copay, unchanged regardless of Part D benefit phase. Only the Zepbound KwikPen formulation is included in the Medicare GLP-1 Bridge; the single-dose vial and single-dose pen formulations are not available through the program. Zepbound is covered under the Medicare GLP-1 Bridge when used to reduce excess body weight and maintain weight reduction.

Novo Nordisk states that all dose strengths of the Wegovy pen and pill are available for $50 per month to patients enrolled in an eligible Medicare Part D plan under the Medicare GLP-1 Bridge program, subject to prior authorization and a covered FDA-approved indication.

Separately, CMS negotiated a Medicare maximum fair price of $274 for a 30-day supply of the selected drug Ozempic; Rybelsus; Wegovy (Novo Nordisk Inc.), taking effect January 1, 2027.

Compounded products. Measured lists Compounded Semaglutide as "No insurance required" with medication included in the membership price, from $119/mo (as published August 5, 2026). Compounded medications are not reviewed or approved by the FDA for safety or effectiveness.

If the packet is denied

A denial is a decision with a deadline attached. An enrollee must file an internal appeal within 180 days (6 months) of receiving notice that the claim was denied. When a plan denies a claim it is required to notify the enrollee of the reason the claim was denied, and a claimant has the right to a full and fair review, including the opportunity to review and respond with written comments, documents, and records to any evidence or rationale under consideration. An internal appeal may be filed by the consumer or by a consumer's authorized representative designated in writing.

The clinical file you already assembled carries over to an appeal of the denial.

Records to hold onto

An appellant should keep the Explanation of Benefits forms or letters showing what payment or services were denied. An appellant should keep notes and dates from any phone conversations with the insurance company or doctor relating to the appeal, including the day, time, name, and title of the person spoken to and details about the conversation. An appellant should keep their original documents and submit copies to the insurance company, but must send the insurance company the original request for an internal appeal and the original request to have a third party file the appeal.